Back to Screener

Mereo BioPharma Group plc American Depositary Shares (MREO)

Price$0.34

Favorite Metrics

Price vs S&P 500 (26W)-91.57%
Price vs S&P 500 (4W)-11.07%
Market Capitalization$51.92M

All Metrics

Book Value / Share (Quarterly)$0.05
P/TBV (Annual)9.00x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.04
Price vs S&P 500 (YTD)-23.36%
EPS (TTM)$-0.05
10-Day Avg Trading Volume1.83M
EPS Excl Extra (TTM)$-0.05
EPS (Annual)$-0.05
ROI (Annual)-65.04%
Gross Margin (Annual)73.40%
Cash / Share (Quarterly)$0.05
ROA (Last FY)-56.62%
EBITD / Share (TTM)$-0.05
ROE (5Y Avg)-50.82%
Cash Flow / Share (Annual)$-0.04
P/B Ratio1.27x
P/B Ratio (Quarterly)1.44x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-8.46x
ROA (TTM)-72.88%
EV / EBITDA (TTM)0.11x
EPS Incl Extra (Annual)$-0.05
Current Ratio (Annual)5.40x
Quick Ratio (Quarterly)10.38x
3-Month Avg Trading Volume10.72M
52-Week Price Return-84.20%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.05
P/S Ratio (Annual)103.85x
Asset Turnover (Annual)0.15x
52-Week High$3.05
EPS Excl Extra (Annual)$-0.05
CapEx CAGR (5Y)91.99%
26-Week Price Return-82.83%
Quick Ratio (Annual)5.38x
13-Week Price Return-53.03%
Total Debt / Equity (Annual)0.09x
Current Ratio (Quarterly)10.46x
Enterprise Value$10.933
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-8375.60%
Cash / Share (Annual)$0.09
3-Month Return Std Dev72.45%
Net Income / Employee (TTM)$-1
ROE (Last FY)-70.94%
Net Interest Coverage (Annual)-1.79x
EPS Basic Excl Extra (Annual)$-0.05
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.05
ROI (TTM)-83.24%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.08
Price vs S&P 500 (52W)-119.29%
Year-to-Date Return-19.22%
5-Day Price Return5.19%
EPS Normalized (Annual)$-0.05
ROA (5Y Avg)-74.73%
Net Profit Margin (Annual)-8375.60%
Month-to-Date Return2.00%
Cash Flow / Share (TTM)$-4.46
EBITD / Share (Annual)$-0.05
Operating Margin (Annual)-8021.40%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-39.82%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.05
P/TBV (Quarterly)1.46x
P/B Ratio (Annual)8.91x
Book Value / Share (Annual)$0.08
Price vs S&P 500 (13W)-55.89%
Beta0.33x
Revenue / Share (TTM)$0.00
ROE (TTM)-83.24%
52-Week Low$0.20

Industry Peers — Pharmaceuticals(309)

SymbolP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
MREOMereo BioPharma Group plc American Depositary Shares
$0.34
LLYEli Lilly & Co.
13.45x44.70%83.04%27.59%$919.90
JNJJohnson & Johnson
5.82x7.87%67.95%14.90%$230.69
ABBVABBVIE INC.
5.97x8.57%71.62%-2.88%$203.71
MRKMerck & Co., Inc.
4.51x1.31%78.55%21.23%$117.10
AZNAstraZeneca PLC
5.39x8.63%81.31%21.88%$200.69
NVSNovartis AG
4.87x8.91%75.82%15.26%$150.99
NVONovo-Nordisk A/S
3.74x6.43%80.98%20.66%$40.46
ABTAbbott Laboratories
3.71x6.59%56.50%8.20%$96.00
PFEPfizer Inc.
2.50x-1.64%75.81%-3.51%$27.52
BMYBristol-Myers Squibb Co.
2.52x-0.22%72.63%$59.13

About

Mereo BioPharma is a UK-based biopharmaceutical company developing treatments for rare genetic disorders. Its lead candidates are setrusumab for osteogenesis imperfecta and alvelestat for alpha-1 antitrypsin deficiency-related lung disease, both in late-stage clinical development.